The marker in question is the triglyceride-glucose index, commonly abbreviated as TyG. It is derived from fasting plasma glucose and fasting triglyceride levels, both of which are inexpensive and widely available in standard blood panels. The index serves as a practical surrogate for insulin resistance, the underlying metabolic dysfunction in which the body’s tissues respond poorly to insulin and glucose regulation gradually deteriorates. Because insulin resistance precedes type 2 diabetes by years or even decades, researchers have long sought accessible ways to quantify it without resorting to costly clamp studies or specialized assays.

What makes the new study distinctive is its treatment of time. A single TyG measurement captures insulin resistance at one moment, but metabolic health is dynamic: people’s glucose and lipid levels fluctuate with diet, weight, illness, and aging. To account for this, the research team, led by Fang Duan and Yujian Fu of the People’s Hospital of Anji in Zhejiang Province, calculated a cumulative average TyG index, or CumAvgTyG. This was defined as the arithmetic mean of fasting TyG values measured at two separate waves of the survey, in 2011–2012 and again in 2015. The approach essentially averages a person’s metabolic burden across a multi-year window, smoothing out short-term noise and capturing sustained insulin resistance rather than a transient spike.

The data came from the China Health and Retirement Longitudinal Study, known as CHARLS, a nationally representative survey of middle-aged and older Chinese adults. The investigators identified participants with prediabetes at the 2011–2012 baseline wave. Prediabetes—blood glucose levels elevated above normal but below the diabetic threshold—is a critical clinical juncture: many people with the condition progress to diabetes, but others remain stable or even revert to normal glucose metabolism. Distinguishing between these trajectories has been a persistent challenge, because conventional single-point measures offer limited predictive power.

From the original prediabetic cohort, the researchers excluded anyone who already had diabetes by 2015, as well as participants whose diabetes-free status in 2015 could not be reliably ascertained. The final analytic sample comprised 1,958 adults with a mean age of 58.5 years, just over half of whom were women. The outcome of interest was clinically recognized diabetes by 2018, defined as a participant-reported physician diagnosis of diabetes and/or the use of glucose-lowering medication or insulin. This definition captures diabetes that has been detected and treated in real-world clinical practice, rather than diabetes identified solely through research screening.

The results were striking. Over the follow-up period, 88 participants—4.5 percent of the cohort—developed clinically recognized diabetes. In a logistic regression model fully adjusted for age, sex, body mass index, smoking status, drinking status, and baseline glycated hemoglobin (HbA1c), each one-standard-deviation increase in CumAvgTyG was associated with 50 percent higher odds of developing clinically recognized diabetes (odds ratio 1.50, 95 percent confidence interval 1.21 to 1.86, P less than 0.001). The adjustment for baseline HbA1c is particularly important, because it means the association held even after accounting for how elevated participants’ blood sugar already was at the start of the study.

When the researchers divided participants into tertiles—three groups based on their CumAvgTyG values—the contrast between the extremes was even more pronounced. Those in the highest tertile had nearly three times the odds of clinically recognized diabetes compared with those in the lowest tertile (odds ratio 2.89, 95 percent confidence interval 1.56 to 5.35, P less than 0.001), and the trend across tertiles was statistically significant. Restricted cubic spline analysis, a flexible statistical technique for examining dose-response relationships, confirmed an overall association (P for overall association 0.001) while finding no evidence of nonlinearity (P for nonlinearity 0.850). In plain terms, the relationship between cumulative TyG and diabetes risk appears to rise steadily across the range of values, without a threshold effect or a plateau—every increment in sustained insulin resistance carries additional risk.

The findings carry practical implications for clinical practice and public health. TyG requires no equipment beyond a standard fasting blood draw and a calculator, making it feasible even in resource-limited settings where sophisticated insulin assays are unavailable. The study’s message is that serial measurement matters: a person whose TyG remains persistently high across several years is in a fundamentally different risk category than someone whose value is high at one visit and normal at the next. For the vast population of people living with prediabetes—estimated in the hundreds of millions worldwide—repeated TyG tracking could help clinicians decide who needs the most intensive lifestyle intervention, closer monitoring, or earlier pharmacological consideration.

Several caveats deserve attention. The outcome was clinically recognized diabetes, meaning the study captures diagnosed and treated disease; some participants may have developed undiagnosed diabetes that would not have been counted. The outcome relied on self-reported physician diagnosis or medication use, which introduces the possibility of recall or reporting error. Residual confounding cannot be excluded in any observational study, even one with careful statistical adjustment, and the findings derive from a Chinese cohort of middle-aged and older adults, so generalizability to other populations and age groups requires further study. The study was supported by the Medical and Health Science Program of Zhejiang Province and the Zhejiang Province Traditional Chinese Medicine Science and Technology Project, with the funding bodies having no role in the design, analysis, or publication decisions.

Even with those limitations, the study adds to a growing body of evidence that cumulative exposure measures outperform single snapshots in metabolic epidemiology. The same cumulative-average logic has been applied to blood pressure, cholesterol, and body mass index, and the present findings extend it to insulin resistance surrogates in a prediabetic population. For researchers, the work underscores the value of longitudinal cohorts like CHARLS, which make such analyses possible. For clinicians and patients alike, the takeaway is deceptively simple: in prediabetes, what matters most may not be any single blood test result, but the sustained metabolic trajectory it reflects. Two cheap measurements taken years apart, averaged together, may flag the people who need help before diabetes takes hold.

Subject of Research: Cumulative triglyceride-glucose index and diabetes risk in adults with prediabetes

Article Title: Association between CumAvgTyG and clinically recognized diabetes among middle-aged and older adults with prediabetes: a prospective cohort study from CHARLS

Article References: Duan, F., Fu, Y., Pan, S., Gao, F., Zheng, X., & Zhao, W. (2026). Association between CumAvgTyG and clinically recognized diabetes among middle-aged and older adults with prediabetes: a prospective cohort study from CHARLS. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02629-9

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02629-9

Keywords: triglyceride-glucose index, prediabetes, type 2 diabetes, insulin resistance, CHARLS, prospective cohort, HbA1c, metabolic syndrome, epidemiology, endocrinology, blood glucose, China

The triglyceride-glucose index, usually abbreviated TyG, is calculated from the logarithm of the product of fasting triglyceride and fasting glucose concentrations. It has become a popular low-cost proxy for insulin resistance, the metabolic state in which tissues respond poorly to the hormone insulin and in which circulating fatty acids and sugars remain chronically elevated. Because insulin resistance sits upstream of type 2 diabetes, fatty liver disease, and atherosclerosis, the TyG index and a family of derivatives that combine it with measures of body size have been studied extensively as predictors of cardiovascular events. What has remained murky is the mechanism: does a high TyG score simply flag people destined for blocked coronary arteries, or does the metabolic environment itself begin to remodel the heart in ways that can be observed and quantified?

To answer that question, a team led by investigators at the China Three Gorges University affiliated Yichang Central People’s Hospital, working with collaborators at Ruhr University Bochum, the University of Glasgow, the University of Milan, and other European centers, turned to the UK Biobank, a vast biomedical database containing detailed imaging and health records for hundreds of thousands of participants. From this resource they identified 31,828 individuals who were free of ischemic heart disease at baseline and who had undergone cardiac magnetic resonance imaging, the gold-standard technique for measuring the volumes and pumping function of every cardiac chamber. For each participant the researchers computed the TyG index along with three obesity-composite derivatives: TyG-BMI, which incorporates body mass index; TyG-WC, which incorporates waist circumference; and TyG-WHtR, which incorporates waist-to-height ratio.

During the follow-up period, 1,768 participants developed incident ischemic heart disease, the umbrella term for conditions in which narrowed or blocked coronary arteries starve the heart muscle of oxygen, including angina and myocardial infarction. Using multivariable Cox proportional hazards models that adjusted for a broad range of demographic, lifestyle, and clinical confounders, the team found that every one of the TyG-related indices was positively and independently associated with the risk of a future cardiac event, with all associations reaching a statistical significance level below 0.001. Restricted cubic spline analyses indicated that the relationships were essentially continuous, meaning that risk climbed steadily with rising index values rather than appearing only above some threshold.

The ranking of the four indices carried its own message. TyG-WHtR, the version that folds in waist-to-height ratio, showed the strongest association with incident disease, with a hazard ratio of 1.221. The plain TyG index followed closely at 1.210, then TyG-WC at 1.200, and finally TyG-BMI at 1.163. The authors suggest that waist-to-height ratio, which captures central or visceral adiposity more faithfully than overall body mass, may make TyG-WHtR the preferred metabolic risk surrogate among the indices evaluated. Central fat depots are metabolically active, releasing free fatty acids and inflammatory signaling molecules directly into the portal circulation, and their combination with a glucose-lipid marker appears to sharpen the predictive signal considerably.

The truly novel step, however, came from the imaging. Because every participant had high-resolution cardiac magnetic resonance data, the researchers could ask whether the structural and functional parameters of the heart, measured at baseline, statistically mediated the link between metabolic score and later disease. Counterfactual mediation analysis, a technique that estimates how much of an observed association flows through an intermediate variable, revealed that subclinical remodeling of the heart accounted for a meaningful fraction of the effect. Left ventricular end-diastolic volume mediated 7.57 percent of the association, left ventricular end-systolic volume mediated 7.60 percent, and left ventricular ejection fraction, a measure of pumping efficiency, mediated 3.49 percent.

Even more impressive were the contributions from the chambers that are often overlooked in routine cardiology. The maximum volume of the left atrium, the receiving chamber that cushions the left ventricle with stored blood, mediated 21.09 percent of the TyG-disease association, the highest proportion of any parameter studied. On the right side of the heart, right ventricular end-diastolic volume mediated 18.67 percent and maximum right atrial volume mediated 14.83 percent. Taken together, these figures paint a picture of a heart that responds to early metabolic injury as a whole organ, with all four chambers undergoing subtle enlargement and functional drift long before a cardiologist would detect anything wrong with a stethoscope or an electrocardiogram.

Why would insulin resistance deform the heart in this way? The study’s authors and the broader literature point to several converging mechanisms. Chronically elevated free fatty acids force the myocardium to shift its fuel preference toward fat oxidation, a less oxygen-efficient metabolic route that promotes the accumulation of lipid intermediates within cardiac cells and can impair contractile proteins. Hyperinsulinemia activates growth signaling pathways in heart muscle, encouraging hypertrophy and fibrosis. Systemic inflammation and oxidative stress, both hallmarks of the insulin-resistant state, damage the microvasculature that feeds the heart wall and stiffen the extracellular matrix between cells. Epicardial adipose tissue, the fat layer wrapped around the heart itself, expands in metabolically unhealthy individuals and secretes pro-inflammatory cytokines directly into the myocardium. Each of these processes could plausibly enlarge atrial and ventricular chambers and gradually erode pumping reserve.

The clinical implications are considerable. Ischemic heart disease remains the leading cause of death worldwide, and a large share of first heart attacks occur in people who were never identified as high risk by conventional screening. A cheap, reproducible blood-derived index that can be combined with a tape-measure measurement of waist and height offers primary care physicians a practical early warning tool. The mediation findings add a mechanistic dimension: if part of the metabolic risk travels through structural cardiac remodeling, then imaging-based surveillance of high-TyG patients, particularly of atrial volumes, could in principle identify subclinical disease at a stage when aggressive lifestyle intervention and metabolic therapy might still alter the trajectory. The left atrium’s prominent mediating role is especially intriguing, since atrial enlargement is also a well-established substrate for atrial fibrillation, suggesting that metabolic injury may simultaneously set the stage for both ischemic and rhythm-related cardiac disease.

The authors are careful to frame the work as observational. Mediation analysis in cohort data can quantify statistical pathways but cannot prove causation with the certainty of a randomized trial, and residual confounding, measurement error in a single baseline blood sample, and the particular demographics of the UK Biobank population all temper generalization. Cardiac magnetic resonance imaging is also expensive and unlikely to enter routine screening for every patient with an elevated TyG score. Nevertheless, the scale of the cohort, the rigor of the adjustment, and the consistency of the associations across all four chambers give the findings substantial weight. They suggest that the heart is exquisitely sensitive to its metabolic environment, and that the earliest fingerprints of that sensitivity can be read from a simple blood draw and a measuring tape years before disease declares itself. As metabolic syndrome continues to spread across aging populations, tools that translate everyday laboratory values into a structural forecast of cardiac health may become indispensable allies in the fight against the world’s most lethal disease.

Subject of Research: The association between triglyceride-glucose index markers of insulin resistance and ischemic heart disease risk mediated by subclinical cardiac remodeling

Article Title: A structural cardiac pathway mediates the risk of ischemic heart disease from TyG-related indices: A prospective cohort study

Article References: Fan, Z., Liu, X., Shi, T., Yang, C., Huang, Y., Sieme, M., Tangos, M., Li, B., Sasko, B., Gao, W., Huang, J., Wintrich, J., Khan, M., Aweimer, A., Mügge, A., Maffia, P., Pellicori, P., Akin, I., van Heerebeek, L., … Yang, J. (2026). A structural cardiac pathway mediates the risk of ischemic heart disease from TyG-related indices: A prospective cohort study. BMC Medicine. https://doi.org/10.1186/s12916-026-05250-8

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05250-8

Keywords: insulin resistance, triglyceride-glucose index, ischemic heart disease, cardiac remodeling, cardiac magnetic resonance, UK Biobank, left atrial volume, mediation analysis, cardiovascular risk, metabolic syndrome, ventricular function, prospective cohort study

The concept of metabolically healthy obesity has long divided the field. Some individuals with elevated body mass index maintain normal blood pressure, glucose metabolism and blood lipids, while others with the same degree of excess weight develop hypertension, dysglycemia and dyslipidemia. Whether the healthy phenotype is a stable state or merely an early stage on the road to disease remains contested, and the answer matters enormously for screening and prevention. Asian populations complicate the picture further, because they develop obesity-related complications at lower body mass index thresholds than European populations, which is why the study used the Asian-specific cutoff of 23 kilograms per square meter rather than the World Health Organization’s global threshold of 25. Healthcare workers, paradoxically, show higher rates of obesity than the general population despite their medical knowledge, making them an instructive group in which to study the transition from apparent health to metabolic dysfunction.

The research team recruited 297 employees of an urban Malaysian academic medical centre through voluntary convenience sampling. Eligible participants had a body mass index of at least 23 kilograms per square meter and no known cardiometabolic disease, meaning the cohort represented people who would typically pass an occupational health check without raising alarms. Each participant underwent a detailed anthropometric assessment, including neck circumference, waist circumference and hip circumference, alongside bioelectrical impedance analysis, a technique that estimates body composition by measuring how the body resists a weak electrical current. Because fat-free mass, which is largely muscle and water, conducts electricity well while fat resists it, the method can partition body weight into fat mass and fat-free mass with reasonable accuracy for population studies. Blood pressure, fasting glucose and lipid profiles completed the picture, allowing the researchers to classify each person as metabolically healthy or unhealthy.

The classification criteria were strict. Metabolically healthy overweight or obesity, abbreviated MHOO, required the complete absence of any metabolic abnormality: no dysglycemia, no elevated blood pressure and no dyslipidemia. Anyone with even one of these features was classified as metabolically unhealthy overweight or obesity, or MUOO. By this standard, only 100 of the 297 participants, or 33.67 percent, qualified as metabolically healthy. The proportion shrank as body mass index rose. At the obesity threshold of 30 kilograms per square meter, 85.32 percent of participants were metabolically unhealthy. Elevated blood pressure emerged as the predominant abnormality, a finding with particular relevance for Asian populations, in which hypertension-related cardiovascular disease often develops at lower body mass indices than in other groups.

When the researchers compared the two phenotypes, the metabolically unhealthy group carried both more fat mass and more fat-free mass than their healthier counterparts. That second observation is the more intriguing one, because fat-free mass expansion is often assumed to be benign or even protective. The correlation analysis revealed a clear division of labour among the simple measurements. Body mass index, waist circumference, hip circumference and waist-to-height ratio all correlated strongly with fat mass, with Spearman coefficients ranging from 0.75 to 0.93, confirming that these indices essentially track how much fat a person carries. Neck circumference and waist-to-hip ratio, by contrast, correlated better with fat-free mass, with coefficients of 0.68 and 0.41 respectively. Neck circumference also showed a moderate correlation of 0.44 with the triglyceride-glucose index, an insulin-resistance marker calculated from fasting triglycerides and glucose that has gained popularity as a cheap surrogate for more invasive metabolic testing.

To determine which measurements independently predicted metabolic status, the team built multivariable logistic regression models adjusted for sociodemographic factors, body composition metrics and the other anthropometric indices. After all adjustments, only neck circumference retained a modest but statistically significant association with metabolically unhealthy status, with an adjusted odds ratio of 1.15 per unit increase and a 95 percent confidence interval of 1.01 to 1.32. The association weakened when the triglyceride-glucose index was added to the model, a pattern that suggests neck circumference may act partly through insulin resistance rather than as an independent risk marker. In other words, a thicker neck may not itself cause metabolic disease, but it appears to flag the same underlying physiology that drives it.

The exploratory mediation analyses pushed this interpretation further. Using parallel mediation models, the researchers tested whether fat mass and fat-free mass explained the link between anthropometric measurements and metabolic risk. Both expansions of fat and lean mass appeared to mediate the association, but the pattern of correlations hinted at something more specific: a predilection for upper-body expansion of fat-free mass may be linked with metabolically unhealthy obesity. This is where the neck measurement earns its place at the table. The neck houses not only subcutaneous fat but also substantial muscle and other lean tissue, and upper-body fat depots are metabolically more active and more harmful than those in the lower body. Fat stored in and around the trunk and upper body drains directly into the portal circulation, flooding the liver with free fatty acids and promoting insulin resistance, whereas gluteofemoral fat is comparatively protective. If neck circumference captures upper-body lean tissue expansion along with fat, it may serve as a composite marker of a metabolically adverse body composition pattern that waist measurements alone miss.

The technical details matter for anyone hoping to translate these findings into practice. Bioelectrical impedance, while convenient and inexpensive, estimates rather than directly measures body composition, and its accuracy varies with hydration status and body geometry. Computed tomography and magnetic resonance imaging remain the gold standards for quantifying visceral fat and regional muscle mass, but they are impractical for population screening. The triglyceride-glucose index, like neck circumference, is attractive precisely because it costs almost nothing to obtain. The study’s cross-sectional design also imposes limits: it captures a single moment in time, so it cannot establish whether neck circumference predicts the future development of diabetes or cardiovascular disease, only that it is associated with current metabolic status. The authors themselves describe the mediation findings as exploratory and call for confirmation in larger cohorts, and the convenience sampling of healthcare workers at a single urban centre may limit generalizability, particularly since healthcare workers differ from the general population in activity levels, health literacy and access to care.

Even with those caveats, the study carries a message that resonates well beyond Malaysian hospitals. Metabolic disturbance is common among people who consider themselves healthy and who would rarely be screened aggressively, because they carry excess weight but no diagnosis. Elevated blood pressure, the most frequent abnormality in this cohort, is both silent and treatable, which makes finding it early genuinely consequential. The study also challenges the comfortable narrative that muscle mass is always protective. Fat-free mass expansion, at least when concentrated in the upper body, may travel alongside insulin resistance rather than against it, a nuance that could reshape how clinicians interpret body composition data from impedance scales increasingly found in gyms and clinics.

For now, the practical takeaway is modest but concrete. A tape measure around the neck, a measurement that takes seconds and requires no laboratory, may help clinicians identify patients with overweight or obesity who deserve closer metabolic scrutiny, especially in Asian populations where risk arrives at lower body mass indices. The researchers, led by Quan-Hziung Lim and Lee-Ling Lim of Universiti Malaya, published their work open access so that other teams can test the hypothesis in larger and more diverse cohorts. If the neck circumference signal survives that scrutiny, one of medicine’s simplest instruments may gain a new role in the fight against two of its most burdensome diseases. Until then, the study stands as a reminder that the body’s metabolic story is written in more places than the waistline, and that some of those places are hiding in plain sight, just below the chin.

Subject of Research: Anthropometric and body composition determinants of metabolically healthy versus unhealthy overweight/obesity in Malaysian healthcare workers

Article Title: Anthropometric and body composition determinants of metabolically healthy and unhealthy overweight/obesity: an analysis among Malaysian healthcare workers

Article References: Lim, Q.-H., Packrisamy, D., Ong, J. S., Kang, M. L., Hee, N. K. Y., Sarvanandan, T., Ooi, Y. G., Khoo, J. K., Ratnasingam, J., Vethakkan, S. R., & Lim, L.-L. (2026). Anthropometric and body composition determinants of metabolically healthy and unhealthy overweight/obesity: an analysis among Malaysian healthcare workers. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02530-5

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02530-5

Keywords: obesity, metabolic syndrome, neck circumference, body composition, anthropometry, insulin resistance, hypertension, bioelectrical impedance, fat-free mass, triglyceride-glucose index, Malaysia, healthcare workers

The retrospective cohort study drew on the Pediatric Intensive Care database, a de-identified repository of records from the Children’s Hospital of Zhejiang University School of Medicine covering the years 2010 to 2019. The analysis included 3,533 critically ill children aged between 29 days and 18 years. The researchers asked two related questions: whether a child’s baseline CTI value on admission predicted death within 30 days, and whether the way that value changed over the course of the hospital stay, its trajectory, carried additional prognostic information. Both answers turned out to be yes, and the magnitude of the associations was striking.

Statistically, each interquartile range increase in baseline CTI, meaning the jump from roughly the 25th to the 75th percentile of the distribution, was independently associated with a 50 percent higher risk of 30-day all-cause mortality, with an adjusted hazard ratio of 1.50 and a 95 percent confidence interval of 1.23 to 1.84. Importantly, this association held after adjustment for confounders, suggesting that CTI captures physiological information beyond what conventional measures provide. The team also demonstrated that CTI discriminated between survivors and non-survivors better than the triglyceride-glucose index alone or C-reactive protein alone, and that adding CTI to the PRISM model, a widely used pediatric risk-of-mortality score, significantly improved its performance.

Beyond the continuous association, the researchers identified a clinically practical threshold. A CTI cutoff of 10.42 divided the cohort into groups with sharply different fates: children above the cutoff faced roughly a twofold higher mortality risk, with an adjusted hazard ratio of 2.05 and a 95 percent confidence interval of 1.46 to 2.88. A single number, computable from blood tests ordered on virtually every ICU admission, separating patients into a high-risk and lower-risk category is exactly the kind of tool that appeals to frontline clinicians, because it requires no new assays, no specialized equipment, and no additional cost.

The technical logic behind the index reflects a growing recognition that inflammation and metabolic dysregulation are not separate phenomena in critical illness but intertwined processes. C-reactive protein rises rapidly in response to interleukin-6-driven inflammatory signaling, particularly in infection and tissue injury. The triglyceride-glucose index, calculated from fasting triglycerides and glucose, serves as a proxy for insulin resistance, which emerges during the metabolic stress response that accompanies severe illness. When these two axes are combined, the resulting score captures a vicious cycle in which inflammatory cytokines disrupt insulin signaling, and insulin resistance in turn amplifies inflammatory pathways, a feedback loop documented in both adult and pediatric critical care research.

Perhaps the most novel contribution of the study is its longitudinal dimension. Using a latent class growth mixed model, a statistical technique that groups patients by the shape of their repeated measurements over time rather than by any single value, the researchers identified distinct CTI trajectory patterns across the hospital stay. Children whose CTI remained persistently high fared the worst, while those with low-stable trajectories and those with U-shaped trajectories, in which the index initially rose and then fell back, showed significantly lower mortality risk than the high-stable group. This finding suggests that the direction of change matters: a falling CTI may signal resolving inflammation and recovering metabolic balance, whereas a stubbornly elevated index flags ongoing physiological derangement.

This trajectory approach mirrors a broader shift in critical care research away from static snapshots and toward dynamic biomarker monitoring. Previous studies have shown that serial lactate measurements, evolving vital sign patterns, and changing triglyceride-glucose values in adults all carry prognostic weight that single time-point readings miss. Earlier work had also hinted at complexity in pediatric populations specifically, with one prior retrospective cohort reporting a U-shaped relationship between the triglyceride-glucose index and mortality in critically ill children, meaning that both very low and very high values were associated with worse outcomes. The new study extends this line of inquiry by adding the inflammatory component and by formally modeling trajectories rather than isolated readings.

The authors, led by Guomiao Zhang, Huiqin Mei, and Qichao Sheng of the Department of Epidemiology and Health Statistics at Wenzhou Medical University, with Guangyun Mao and Dapeng Li as corresponding authors, emphasize that this is the first study to demonstrate the dual prognostic value of both baseline CTI and its longitudinal trajectories in critically ill children. They position CTI as a simple, dynamic tool for mortality risk stratification in pediatric critical care, one that could complement rather than replace established scoring systems such as PRISM and PIM2, which rely on physiological parameters collected at admission and are known to have imperfect calibration across diverse patient populations.

As with any retrospective, single-database study, important caveats apply. The data come from one Chinese children’s hospital, and the analysis relied on the Pediatric Intensive Care database, which was approved by that institution’s review board as a de-identified dataset exempt from additional consent. Retrospective designs cannot establish causation, and the association between high CTI and mortality does not prove that the index itself is harmful; it may simply be a faithful readout of underlying severity. Missing data were handled with multiple imputation, a standard but imperfect technique, and the researchers themselves note in the broader literature that classifying trajectories over time should be done with caution because different statistical methods can yield different groupings. External validation in independent cohorts, ideally prospective and multi-center, will be needed before CTI thresholds are adopted into routine practice.

Nevertheless, the appeal of the finding lies in its accessibility. In intensive care units around the world, particularly in resource-limited settings where advanced biomarkers and sophisticated scoring infrastructure are scarce, the ability to compute a mortality risk indicator from three routine laboratory values, triglycerides, glucose, and C-reactive protein, could meaningfully improve triage, family counseling, and the intensity of monitoring. If future studies confirm the cutoff of 10.42 and the prognostic significance of trajectory patterns, a calculation scribbled on a chart could become an early warning system for the sickest children, flagging those who need escalation of care before irreversible deterioration sets in. For a field where every hour of delay can matter, a free and fast risk signal drawn from blood already being tested is a compelling proposition.

Subject of Research: Prognostic value of the C-reactive protein-triglyceride glucose index and its trajectories for mortality in critically ill children

Article Title: C-reactive protein-triglyceride glucose index and its dynamic trajectories on all-cause mortality in critically ill children: a longitudinal, retrospective cohort study

Article References: Zhang, G., Mei, H., Sheng, Q., Yin, M., Fang, Y., Ding, Q., Liu, K., Shou, Y., Zhang, X., Shi, F., Mao, Q., Zheng, C., Mao, G., & Li, D. (2026). C-reactive protein-triglyceride glucose index and its dynamic trajectories on all-cause mortality in critically ill children: a longitudinal, retrospective cohort study. Pediatric Research. https://doi.org/10.1038/s41390-026-05481-8

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05481-8

Keywords: C-reactive protein, triglyceride-glucose index, CTI, pediatric intensive care, critical illness, mortality prediction, insulin resistance, inflammation, biomarker trajectories, retrospective cohort study, PRISM score, risk stratification

Type 2 diabetes is far more than a disorder of blood sugar. Persistent hyperglycaemia, insulin resistance and low-grade inflammation conspire to damage the endothelium, the delicate inner lining of blood vessels, setting the stage for atherosclerosis—the buildup of lipid-rich plaques that can rupture and trigger heart attacks and strokes. Oxidative stress and dyslipidaemia compound this damage. Even with modern glucose-lowering therapies, cardiovascular disease remains the leading cause of illness and death among people with type 2 diabetes, which is precisely why researchers are searching for biomarkers that capture the inflammatory dimension of risk beyond conventional lipid panels and glucose measurements.

The focus of the new study is a molecular oddity within the interleukin-12 family of cytokines. Interleukin-12, composed of the p35 and p40 subunits, is a potent driver of inflammatory immunity: it pushes naïve T cells toward the Th1 lineage and stimulates production of interferon-gamma, fuelling vascular inflammation and accelerating plaque formation. Interleukin-35, built from p35 paired with a different partner called Ebi3, does the opposite. Produced mainly by regulatory T cells and regulatory B cells, it suppresses effector immune responses and appears to protect blood vessels from injury. Because both cytokines incorporate the same p35 chain, measuring p35 in the bloodstream provides an integrated snapshot of the net balance between these opposing signals.

To test whether that balance relates to atherogenic risk, the team enrolled 80 adults with type 2 diabetes attending the Katutura Community Health Centre, diagnosing cases according to American Diabetes Association criteria. Participants were excluded if they had malignant disease, autoimmune disorders, pregnancy or recent infection, all of which could distort inflammatory readouts. Blood samples were analysed for full blood counts, erythrocyte sedimentation rate, glycated haemoglobin, fasting glucose, lipid profiles, C-reactive protein and globulins, while plasma p35 concentrations were quantified with a commercial enzyme-linked immunosorbent assay read at 450 nanometres. Patients were then split at the median p35 value of 18.48 picograms per millilitre into low and high groups of 40 each.

The two groups were remarkably well matched on the surface. Age, sex distribution, body mass index, blood pressure and disease duration were all comparable, with roughly 90 percent of the cohort being female. Yet beneath that apparent equivalence, striking metabolic differences emerged. Patients in the high-p35 group had significantly higher fasting glucose, averaging 10.71 versus 8.97 millimoles per litre, and a greater share of them—62.5 percent versus 42.5 percent—fell into the poor glycaemic control category defined by glycated haemoglobin above 8 percent. Most participants were on metformin, which the authors note may have dampened systemic inflammatory markers in both groups.

Indeed, standard inflammation measures told no story at all: C-reactive protein, erythrocyte sedimentation rate, the systemic immune-inflammation index, globulins and the neutrophil-to-lymphocyte ratio were statistically indistinguishable between groups. The lipid machinery, however, told a different tale. Triglycerides were markedly higher in the high-p35 group at 1.93 versus 1.24 millimoles per litre, high-density lipoprotein cholesterol was significantly lower at 0.97 versus 1.09 millimoles per litre, and the triglyceride-to-HDL ratio was substantially elevated. This pattern—more triglyceride-rich particles, less protective HDL—is precisely the profile that promotes lipid retention in arterial walls, foam cell formation and plaque growth.

Composite risk indices sharpened the picture further. The triglyceride-glucose index, a logarithmic measure of insulin resistance that integrates fasting triglycerides and glucose, averaged 9.63 in the high-p35 group versus 8.99 in the low group, with a striking 85 percent of high-p35 patients classified in the high-risk category above 9. The atherogenic index of plasma, calculated from triglycerides and HDL cholesterol, was more than six times higher in the high-p35 group, at 0.25 versus 0.04. Spearman correlation analysis confirmed that p35 levels rose in parallel with triglycerides, the atherogenic index, the triglyceride-to-HDL ratio and the triglyceride-glucose index, while showing a modest inverse relationship with HDL cholesterol. Notably, p35 showed no significant association with fasting glucose alone, suggesting the link runs through triglyceride-rich lipoprotein metabolism rather than glycaemia per se.

The relationship held up under statistical scrutiny. In a multiple linear regression model with the atherogenic index of plasma as the outcome, p35 remained an independent predictor alongside the triglyceride-glucose index, and the association persisted after adjusting for age, sex, body mass index, blood pressure, disease duration and medication use. Receiver operating characteristic analysis then tested whether p35 could actually discriminate high-risk patients: for identifying an elevated atherogenic index it achieved an area under the curve of 0.79, with an optimal threshold above 20.50 picograms per millilitre delivering 65 percent sensitivity and nearly 85 percent specificity, and a positive likelihood ratio of 4.30. Performance for detecting a high triglyceride-glucose index was similar, at an area under the curve of 0.78.

Mechanistically, the findings fit a coherent biological narrative. Excessive interleukin-12 signalling, transmitted through the JAK2-STAT4 pathway, promotes Th1 polarisation and interferon-gamma production, driving macrophage activation, adipose tissue inflammation and impaired insulin signalling—all of which feed insulin resistance and accelerate the transformation of macrophages into lipid-laden foam cells within plaques. Meanwhile, weakened interleukin-35 signalling from regulatory lymphocytes removes a brake on endothelial activation and leukocyte recruitment, allowing vascular inflammation to smoulder. Elevated triglycerides add their own insult through remnant lipoproteins that lodge in the arterial wall and through remodelling reactions that generate more atherogenic apolipoprotein B-containing particles while degrading the anti-inflammatory and cholesterol-efflux functions of HDL.

The authors are careful about the study’s central limitation: because p35 is shared, the assay cannot distinguish whether the signal reflects excess interleukin-12, deficient interleukin-35, or both. Prior studies have consistently reported elevated interleukin-12 in type 2 diabetes, whereas evidence on interleukin-35 remains inconclusive, so separate quantification of each cytokine is the logical next step. Unmeasured medications such as lipid-lowering agents and antihypertensives could also have influenced outcomes, and it remains unknown whether the association is specific to diabetes or reflects a general immune-metabolic response. Even so, the study’s strengths are considerable: a well-matched cohort, pre-powered sample size calculations, multivariable adjustment, and the use of composite indices that capture risk invisible to traditional lipid panels. If validated in larger and more diverse cohorts, a simple blood measurement of this shared cytokine subunit could become a practical immunometabolic tool for spotting cardiovascular danger in diabetic patients long before standard tests raise the alarm.

Subject of Research: The association between circulating IL-12/IL-35 p35 subunit levels and atherogenic risk in African patients with type 2 diabetes

Article Title: The Shared IL‐12/IL‐35 p35 Subunit Is Associated With Heightened Atherogenic Risk in African Patients With Type 2 Diabetes

Article References: Nyambuya, T. M., Shingenge, E., Ndevahoma, F., & Nkambule, B. B. (2026). The Shared IL ‐12/ IL ‐35 p35 Subunit Is Associated With Heightened Atherogenic Risk in African Patients With Type 2 Diabetes. Endocrinology, Diabetes & Metabolism, 9(5), Article e70306. https://doi.org/10.1002/edm2.70306

Image Credits: AI Generated

DOI: 10.1002/edm2.70306

Keywords: type 2 diabetes, interleukin-12, interleukin-35, p35 subunit, atherogenicity, cardiovascular risk, dyslipidaemia, insulin resistance, triglyceride-glucose index, atherogenic index of plasma, inflammation, Namibia

The TyG index has become one of the most popular inexpensive proxies in metabolic research over the past decade. It is computed as the natural logarithm of the ratio of fasting triglycerides, expressed in milligrams per deciliter, to half of fasting glucose. Because both ingredients come from a standard lipid panel and glucose test, the index costs pennies to calculate and requires no insulin assay, no imaging and no specialized equipment. Physiologically, it captures the degree of insulin resistance, the state in which tissues respond weakly to insulin and compensatory metabolic shifts follow. Insulin resistance sits at the heart of type 2 diabetes, fatty liver disease and cardiovascular risk, and a growing body of work has implicated it in skeletal health as well, since bone is not the metabolically inert structure it was once assumed to be but a living organ whose remodeling is sensitive to glucose and lipid handling.

What makes the new study distinctive is its focus on the co-occurrence of two conditions rather than either one alone. Bone mass abnormality—encompassing the low bone density seen in osteopenia and osteoporosis as well as abnormally elevated bone mass—and dyslipidemia, the disturbance of blood cholesterol and triglyceride levels, are usually studied in isolation. Yet in clinical practice they frequently travel together, and patients who carry both face compounded risks: fragile bones that fracture easily combined with the vascular consequences of abnormal lipids. Understanding whether a shared metabolic driver links them has obvious implications for screening, because a marker that predicts the pair simultaneously could direct preventive attention to people who would otherwise slip between the separate checklists of endocrinology and orthopedics.

To probe that question, the research team, which also included Shenggui Gan, Huairong Ren and Junying Tan of the Lusha’er Community Health Service Center in Qinghai’s Huangzhong District, together with Yuan He of the First People’s Hospital of Xining City, classified participants according to standardized diagnostic criteria for both bone mass abnormality and dyslipidemia. The study received ethical approval from the Ethics Committee of Qinghai University School of Medicine under approval number 2023-027, complied with the Declaration of Helsinki, and enrolled only adults aged eighteen or older who provided written informed consent. The setting matters: the work was conducted in a moderate-altitude plateau population in Qinghai Province, China, whose metabolic characteristics may differ from those of lowland populations and which the authors flag as a group warranting particular care in future validation.

Statistically, the investigators deployed an unusually thorough toolkit for a cross-sectional analysis. Multivariate logistic regression estimated the independent association between TyG and comorbidity while controlling for potential confounders. Restricted cubic spline analysis then mapped the shape of the relationship across the full range of index values rather than forcing it into a straight line. Saturation effect analysis searched for a threshold above which additional increases in TyG might stop adding risk. Finally, receiver operating characteristic curves quantified how well TyG discriminated between those with and without the comorbidity, and the DeLong test statistically compared its performance against a rival metric, the combined TyG-BMI index, which blends the metabolic marker with body mass index.

The results coalesced into a striking picture. The restricted cubic spline analysis revealed a nonlinear, J-shaped association between the TyG index and the risk of comorbidity, with a probability value for non-linearity below 0.001. In practical terms, risk was relatively contained across a lower region of index values, then climbed steeply once the index passed into its upper range. Saturation effect analysis suggested a possible inflection near TyG equal to 9.36, hinting at a threshold beyond which the association may flatten—a detail the authors say requires confirmation but which could prove valuable for defining a practical alert zone in population screening.

The discriminatory analysis delivered the study’s most eye-catching number. The TyG index achieved the highest observed area under the curve, or AUC, among all the indices evaluated for identifying comorbidity, registering 0.732 with a 95 percent confidence interval of 0.685 to 0.780. For context, an AUC of 0.5 indicates discrimination no better than a coin flip, while 1.0 indicates perfect separation; a value above 0.7 is generally considered acceptable for a simple clinical marker. Crucially, the DeLong test confirmed that TyG’s advantage was not a statistical fluke: its AUC exceeded that of the combined TyG-BMI index by 0.1703, with a probability value below 0.001. In other words, layering body size onto the metabolic measure actually diluted rather than sharpened its performance for this particular outcome, an outcome that cuts against the intuition that composite indices always outperform their simpler components.

Why would a marker of insulin resistance track so closely with the simultaneous presence of weak bones and abnormal lipids? The authors place the finding within the broader biology of metabolic and skeletal crosstalk. Bone cells respond to insulin, and insulin-resistant states alter osteoblast activity, bone turnover and bone quality. Meanwhile, dyslipidemia is both a product of and a contributor to insulin resistance, with elevated free fatty acids and triglyceride-rich lipoproteins capable of accumulating in bone marrow and perturbing the balance between fat and bone cell lineages. A high TyG value may therefore act as a crude but effective integrator of the shared metabolic milieu from which both conditions emerge, making it a natural candidate for flagging the comorbidity even though it was not designed for that purpose.

The researchers are careful about what their study can and cannot claim. Because it is cross-sectional, capturing participants at a single point in time, it demonstrates association rather than causation; it cannot establish whether insulin resistance drives the joint condition, whether the conditions feed back on metabolism, or whether unmeasured factors explain the link. The authors explicitly state that prospective validation is required before clinical screening use can be recommended, particularly in moderate-altitude populations with unique metabolic characteristics such as the one studied. The work was supported by the Huangzhong Plateau Grand Health Technology Courtyard Qinghai under project qdyjd-2508, and the team declares no competing interests. The article was published open access on 22 September 2026 under a Creative Commons license, received by the journal on 26 June 2026 and accepted on 8 September 2026.

Even with those caveats, the practical appeal is hard to overstate. If the findings replicate in longitudinal cohorts and across diverse geographies, a two-laboratory-value calculation could help clinicians and public health programs identify adults who merit bone density testing and lipid management simultaneously, using infrastructure that already exists in nearly every clinic on earth. In a field where advanced imaging and specialized biomarkers often dominate headlines, the study is a reminder that sometimes the most consequential tools are the cheapest ones—an arithmetic operation performed on numbers that were already sitting in the patient’s chart. The authors position the TyG index not as a diagnostic test but as a low-cost, readily available instrument for population risk stratification, and their data suggest it performs that role with a precision few would have predicted for so humble a formula.

Subject of Research: The association between the triglyceride-glucose index and the comorbidity of bone mass abnormality and dyslipidemia

Article Title: Association of the triglyceride-glucose index with the comorbidity of bone mass abnormality and dyslipidemia: a cross-sectional study

Article References: Ma, J., Gan, S., Ren, H., Tan, J., He, Y., & Dang, Z. (2026). Association of the triglyceride-glucose index with the comorbidity of bone mass abnormality and dyslipidemia: a cross-sectional study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02550-1

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02550-1

Keywords: triglyceride-glucose index, TyG index, insulin resistance, bone mass abnormality, dyslipidemia, comorbidity, osteoporosis, cross-sectional study, risk stratification, metabolic syndrome, bone health, lipid metabolism

Major depressive disorder is far more than a mood condition. Beyond low mood and lost interest, many patients struggle with memory, attention, and executive function—deficits that often persist between depressive episodes and interfere with work, relationships, and daily life. At the same time, researchers have long noted that depression travels with metabolic disturbances such as insulin resistance, and with elevated levels of inflammatory molecules circulating in the blood. What has remained murky is how these threads connect to one another, and why some patients develop cognitive problems while others do not.

The research team, led by investigators at Xiamen Xianyue Hospital affiliated with Xiamen Medical College, recruited 300 people with major depressive disorder—100 men, 100 premenopausal women, and 100 postmenopausal women—along with 150 age- and body mass index-matched healthy controls. Participants were assessed between February 2021 and September 2024 using a battery of measures designed to capture the full biological and clinical picture: the triglyceride-glucose index, a simple calculated marker of insulin resistance; serum neuropeptide Y measured by enzyme-linked immunosorbent assay; inflammatory markers including interleukin-6, tumor necrosis factor-alpha, and C-reactive protein; appetite ratings on a visual analog scale; depression severity on the 17-item Hamilton Depression Rating Scale; and cognition using the Montreal Cognitive Assessment.

The results were striking from the first comparison. Patients with depression showed significantly higher triglyceride-glucose index values, higher neuropeptide Y levels, and greater inflammation than controls, alongside markedly lower cognitive scores. Neuropeptide Y, a peptide released during stress that also regulates appetite and energy balance, was elevated most prominently in premenopausal women—a detail that immediately signaled the importance of sex and reproductive status in the underlying biology.

Correlation analyses deepened the picture. Neuropeptide Y tracked positively with both the triglyceride-glucose index and appetite ratings, with correlation coefficients ranging from 0.43 to 0.52, suggesting that as metabolic dysfunction worsened, the peptide rose in tandem with increased appetite. But the same molecule told a darker story about the brain: it correlated negatively with cognitive performance, with coefficients between −0.35 and −0.46. The stronger a patient’s metabolic derangement and appetite disturbance, the worse their performance on tests of memory and thinking—and once again, these relationships were strongest in premenopausal women.

To test whether neuropeptide Y actually serves as a conduit between metabolism and cognition, the team used a statistical technique called moderated mediation analysis. The findings revealed a layered pathway. Inflammation partially mediated the link between neuropeptide Y and cognitive scores, accounting for roughly 39 percent of the total effect. In other words, high neuropeptide Y appears to fuel inflammatory processes, and those inflammatory signals in turn chip away at cognitive function.

The full chain ran even further back. Neuropeptide Y and inflammation jointly mediated the relationship between the triglyceride-glucose index and cognition, with the joint indirect effect explaining 36.88 percent of the total association. Critically, this mediation was moderated by sex and reproductive status: the pathway was most powerful in premenopausal women, where the indirect effect accounted for 42.37 percent of the total—meaning that in younger women, nearly half of the connection between poor metabolic health and cognitive impairment flows through elevated neuropeptide Y and inflammation.

The authors suggest several mechanisms that could underlie these sex differences. Neuropeptide Y levels are known to vary with estrogen status, and estrogen interacts with both metabolic regulation and immune signaling. Premenopausal women, with higher circulating estrogen, may mount a distinct metabolic and inflammatory response to depression—one in which appetite changes driven by neuropeptide Y are more pronounced, and in which the downstream inflammatory consequences for the brain are amplified. After menopause, this coupling appears to loosen, producing a different risk architecture.

Beyond clarifying mechanism, the study carries immediate clinical promise in the form of a diagnostic tool. The researchers combined four blood measures—the triglyceride-glucose index, neuropeptide Y, interleukin-6, and tumor necrosis factor-alpha—into an integrated biomarker panel and tested its ability to distinguish patients with cognitive impairment using receiver operating characteristic analysis. The panel achieved an area under the curve of 0.869, substantially outperforming the triglyceride-glucose index alone, which managed 0.748. The difference was statistically robust. A simple blood draw, in other words, could one day flag which patients with depression are most at risk of the cognitive dimension of the illness.

The authors caution that the cross-sectional design captures only a snapshot, so cause and effect cannot be definitively established, and longitudinal studies are warranted to confirm whether correcting metabolic dysfunction early can prevent cognitive decline. Still, the implications are considerable. If the pathway holds, interventions targeting insulin sensitivity, neuropeptide Y signaling, or inflammation—tailored to a patient’s sex and reproductive stage—could offer a biological handle on the cognitive symptoms that make depression so disabling. The study is also a reminder that psychiatric illness is embodied: mood, metabolism, immunity, and hormones are not separate stories but a single, sex-specific web, and untangling it may finally explain why the brain falters when the body’s chemistry goes awry.

Neuropeptide Y itself has a long research history that helps explain why it sits at the center of this pathway. It is one of the most abundant neuropeptides in the mammalian nervous system, co-released with norepinephrine during stress, where it classically acts to buffer the cardiovascular and emotional impact of acute stressors. Yet the same peptide is also a potent orexigenic signal, stimulating food intake and promoting fat storage when released in hypothalamic circuits. This dual identity—stress resilience on one hand, metabolic promotion on the other—may account for the seemingly paradoxical findings in the new study, in which higher neuropeptide Y accompanied greater appetite but poorer cognition. Chronic elevation of a peptide designed for short-term stress responses may carry costs that only become apparent over time, particularly in metabolic and immune systems.

The choice of the triglyceride-glucose index as the study’s metabolic anchor reflects broader trends in cardiometabolic research. Unlike direct measures of insulin resistance, which require fasting insulin assays or dynamic testing, the index is computed from routine fasting triglyceride and glucose values, making it inexpensive and easy to deploy in large cohorts and clinical settings. It has been validated across numerous populations as a surrogate for insulin resistance and has repeatedly been associated with adverse outcomes ranging from cardiovascular disease to non-alcoholic fatty liver disease. Its appearance here as a predictor of cognitive impairment in depression extends that literature into psychiatry, and its practicality matters: a marker that requires only a standard metabolic panel could be incorporated into routine psychiatric care far more readily than specialized testing.

The inflammatory markers used in the study likewise represent well-characterized players in the biology of depression. Interleukin-6 and tumor necrosis factor-alpha are pro-inflammatory cytokines that can signal to the brain through both humoral and neural routes, influencing neurotransmitter metabolism, hypothalamic-pituitary-adrenal axis activity, and neuroplasticity. Elevated peripheral inflammation has been reported in subsets of depressed patients for decades, and previous work has linked inflammatory activity to specific symptom dimensions, including fatigue, psychomotor slowing, and cognitive difficulties. The present findings sit comfortably within that tradition while adding a mechanistic twist: inflammation appears not simply as a correlate of depression but as a downstream conduit through which metabolic and neuropeptide signals reach the brain.

The statistical architecture of the study also deserves note. Moderated mediation analysis allows researchers to test both an indirect pathway—whether one variable transmits the effect of another—and whether that transmission differs across subgroups. By applying this framework separately to men, premenopausal women, and postmenopausal women, the investigators could quantify how the same biological chain varies in strength depending on hormonal context. The confidence intervals reported for the indirect effects excluded zero across the full sample and in the premenopausal subgroup, lending statistical weight to conclusions that might otherwise rest on visual inspection of subgroup differences alone.

The diagnostic analysis likewise illustrates methodological principles worth understanding. The area under the receiver operating characteristic curve expresses, on a scale from 0.5 to 1.0, how well a marker separates affected from unaffected individuals, with values above 0.8 generally considered useful discrimination. The jump from 0.748 for the triglyceride-glucose index alone to 0.869 for the four-marker panel, confirmed by a formal comparison test, demonstrates the additive value of measuring multiple biological dimensions rather than any single one. This multibiomarker approach mirrors strategies already standard in cardiovascular risk assessment, where combinations of lipid, inflammatory, and metabolic measures outperform any lone indicator.

Finally, the study’s framing around reproductive stage rather than sex alone points toward a more nuanced future for psychiatric biomarker research. Menopause represents a natural experiment in estrogen withdrawal, and the loosening of the neuropeptide Y–inflammation–cognition coupling observed after menopause suggests that ovarian hormones actively shape how metabolic stress is translated into neural injury. Disentangling these hormonal contributions may ultimately identify which patients benefit most from metabolic or anti-inflammatory interventions, moving psychiatry closer to biologically stratified treatment.

Subject of Research: How neuropeptide Y connects metabolic dysfunction and inflammation to cognitive impairment in major depressive disorder across sex and menopausal status.

Article Title: Interplay of neuropeptide Y, metabolic dysfunction, and inflammation in cognitive impairment of major depressive disorder: a sex-stratified study

Article References: Yuan, Q., Elhassan, M. A. M., Zhang, H., Wang, L., Zhu, X., Wu, Z., Lin, D., & Huang, Z. (2026). Interplay of neuropeptide Y, metabolic dysfunction, and inflammation in cognitive impairment of major depressive disorder: a sex-stratified study. Biology of Sex Differences. https://doi.org/10.1186/s13293-026-00981-y

Image Credits: AI Generated

DOI: 10.1186/s13293-026-00981-y

Keywords: major depressive disorder, neuropeptide Y, cognitive impairment, triglyceride-glucose index, inflammation, insulin resistance, sex differences, menopause, biomarkers, interleukin-6, IL-6, MoCA

The TyG index is calculated using fasting triglyceride and glucose concentrations, usually expressed as the natural logarithm of the product of the two measurements after appropriate unit conversion. In simplified form, the calculation is often represented as ln[fasting triglycerides × fasting glucose ÷ 2]. Triglycerides are circulating fats transported in the bloodstream, while glucose is the body’s primary short-term energy substrate. When both are elevated, the combination may signal impaired insulin action, a metabolic condition commonly known as insulin resistance. In insulin resistance, muscle, liver and fat cells respond less effectively to insulin, prompting the pancreas to produce more of the hormone and the liver to release or generate additional glucose. The TyG index is therefore not a direct measurement of insulin resistance, but it is widely studied as an inexpensive surrogate marker that can be derived from conventional laboratory tests.

The interest in TyG extends beyond blood sugar and lipid metabolism because insulin resistance can influence the cardiovascular system through several biological pathways. Excess insulin may stimulate sympathetic nervous system activity, increase sodium retention by the kidneys and promote changes in vascular smooth muscle. At the same time, metabolic dysfunction can contribute to chronic, low-grade inflammation, oxidative stress and impaired endothelial function. The endothelium, the thin layer of cells lining blood vessels, normally helps regulate vessel relaxation and constriction. When it becomes less responsive, arteries may remain relatively constricted, increasing vascular resistance and potentially pushing blood pressure upward. These mechanisms do not prove that a higher TyG index causes hypertension, but they offer a physiological explanation for why the two measures might appear together.

Elevated blood pressure in adolescence is not simply a temporary inconvenience. Blood pressure naturally fluctuates with physical activity, stress, sleep, body position and the technique used during measurement, which is why pediatric assessment generally requires careful procedures and, when necessary, repeated readings. Even so, persistently elevated values can indicate that the cardiovascular system is already experiencing increased mechanical stress. Over time, high pressure can promote thickening of the heart’s left ventricle, stiffening of arteries and subtle damage to the kidneys and blood vessels. Teenagers with elevated blood pressure are also more likely to carry that risk into adulthood, particularly when high blood pressure occurs alongside obesity, abnormal cholesterol levels or impaired glucose regulation. A marker that could help identify this cluster of risks would be valuable, especially in settings where more complex metabolic testing is impractical.

The study’s focus on U.S. adolescents aged 12 to 17 is particularly relevant because this period includes rapid hormonal, physical and behavioral change. Puberty can temporarily alter insulin sensitivity, body composition and blood pressure, making it difficult to distinguish normal development from early metabolic disease. Diet, physical activity, sleep duration, stress and socioeconomic conditions can also influence both the TyG index and blood pressure. For example, diets high in refined carbohydrates and saturated fats may raise glucose and triglyceride levels, while insufficient sleep and sedentary behavior can affect endocrine regulation and vascular function. A population-level analysis can help researchers determine whether the relationship between TyG and elevated blood pressure persists across the diverse environments in which American teenagers grow up.

The investigators describe their work as an examination of the association between TyG and elevated blood pressure rather than a trial of a treatment or a demonstration of cause and effect. That distinction is essential. If adolescents with higher TyG values are more likely to have elevated blood pressure, the result would show that the two characteristics tend to occur together. It would not establish whether insulin resistance raises blood pressure, whether high blood pressure contributes to metabolic abnormalities, or whether both arise from a third factor such as excess adiposity, diet, chronic stress or low physical activity. Statistical adjustment can reduce the influence of some confounding variables, but it cannot transform an observational association into proof of causation. The strength and clinical usefulness of the relationship would also depend on how accurately blood pressure and fasting laboratory values were measured, how representative the participants were, and whether the association remained after accounting for age, sex, race and ethnicity, body mass index and other health factors.

For clinicians, the appeal of the TyG index lies in its accessibility. Fasting glucose and triglycerides are already familiar components of metabolic evaluation, and the calculation requires no specialized imaging, insulin infusion or advanced laboratory platform. A reliable association could eventually help clinicians recognize adolescents who merit closer monitoring of blood pressure and broader cardiometabolic health. However, the index should not be interpreted as a stand-alone diagnostic test. A single TyG value can be influenced by fasting duration, recent illness, medications, laboratory variation and normal biological fluctuation. Blood pressure itself must be measured with an appropriately sized cuff and interpreted according to pediatric age, sex and height-based standards. Any screening strategy would therefore need to combine TyG with established clinical information rather than replace a full assessment.

The subject has also attracted broad public interest because metabolic risk is increasingly visible in younger age groups, but the message requires care. A high TyG index would not mean that a teenager is destined to develop cardiovascular disease, just as a normal value would not guarantee lifelong protection. Risk is dynamic and can be modified through changes in nutrition, movement, sleep and treatment of underlying conditions. For young people, effective prevention should avoid stigma and focus on family-wide habits and access to appropriate medical care. Policies that improve the availability of nutritious food, safe opportunities for physical activity and regular primary care may have a larger population impact than any single biomarker. The TyG index could become one piece of that prevention framework if future studies confirm that it improves risk prediction beyond blood pressure, body size and standard metabolic measurements.

The publication arrives at a time when researchers are searching for practical ways to connect adolescent health data with the earliest signs of adult cardiovascular disease. The study by Tang and colleagues addresses that gap by testing whether a marker originally developed to reflect metabolic dysfunction also tracks with elevated blood pressure during adolescence. Its central hypothesis is biologically plausible and clinically relevant, but the implications depend on the detailed findings, the design of the underlying analysis and the consistency of results across different groups of young people. Follow-up research will be needed to determine whether TyG predicts persistent hypertension, whether it adds information beyond body mass index and waist circumference, and whether lowering the index through lifestyle or medical intervention changes blood-pressure trajectories. For now, the study places a compact metabolic calculation at the center of a larger warning: cardiovascular risk may begin accumulating long before adulthood, and the clues may already be visible in ordinary blood tests.

Subject of Research: Association between the triglyceride-glucose (TyG) index and elevated blood pressure among U.S. adolescents aged 12–17 years.

Article Title: Association between triglyceride-glucose index and elevated blood pressure among U.S. adolescents aged 12–17.

Article References: Tang, J., Shi, Y., Jiao, X. et al. Association between triglyceride-glucose index and elevated blood pressure among U.S. adolescents aged 12–17. Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05407-4

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05407-4

Keywords: triglyceride-glucose index, TyG index, elevated blood pressure, adolescent health, insulin resistance, cardiovascular risk, hypertension, metabolic health

As the prevalence of T2DM continues to rise globally, effective risk assessment tools are imperative for improving patient management and guiding healthcare interventions. The traditional approaches to evaluating the health status of T2DM patients primarily rely on standard glycemic measures such as HbA1c levels and fasting glucose. However, these methods, while valuable, often fall short when it comes to comprehensively assessing the multifaceted nature of diabetes and its complications.

The study’s authors argue for a paradigm shift in the way healthcare providers approach diabetes risk evaluation. By integrating the TGI—a metric that combines triglyceride levels with glucose levels—alongside novel anthropometric measures, they propose a more holistic view of a patient’s metabolic state. This innovative approach recognizes that traditional measures alone may not capture crucial information related to lipid metabolism and fat distribution, both of which can profoundly influence morbidity and mortality outcomes in T2DM patients.

The TGI has emerged as an important biomarker due to its association with insulin resistance and metabolic syndrome. Elevated triglyceride levels, when combined with impaired glucose metabolism, paint a troubling picture of an individual’s health status. In their findings, the researchers indicate that patients exhibiting high TGI values are significantly more likely to experience adverse health outcomes, including an increased risk of cardiovascular diseases and mortality.

Additionally, the anthropometric measures included in the study, such as waist circumference and body mass index (BMI), provide further insight into fat distribution and obesity. These measures are critical, as they help to identify patients who may be at heightened risk due to central obesity. The integration of these anthropometric indicators with the TGI could allow for more tailored interventions that address both the metabolic and physical health of individuals with T2DM.

The research methodology employed in this groundbreaking study is robust and meticulously designed. It encompasses a diverse cohort of patients with T2DM, ensuring that the findings are applicable to a wide range of demographic groups. By employing longitudinal tracking of health outcomes, the authors were able to establish clear correlations between the combined metrics and various health outcomes over time. This prospective design lends significant weight to their conclusions, illustrating not just immediate risks but long-term implications of TGI and anthropometric measures.

An intriguing aspect of this study is its potential to influence clinical practice. With diabetes presenting complex challenges, healthcare professionals are in continuous search of effective tools for risk stratification. The proposed combination of TGI and anthropometric measures could emerge as a standard practice in assessing the mortality risk of T2DM patients, leading to more informed decision-making regarding treatment strategies and lifestyle interventions.

Moreover, as diabetes care becomes increasingly personalized, the findings of this research support the need for individualized treatment plans that consider a patient’s metabolic profile. Healthcare providers can use the combined measures to identify patients who may benefit from intensified lifestyle modifications, pharmacotherapy, or more frequent monitoring, ultimately aiming to reduce the incidence of diabetes-related complications and improve quality of life.

As the scientific community continues to grapple with the implications of rising diabetes rates, the need for research like this will only grow. Studies emphasizing the interplay between metabolic indicators and patient outcomes are vital for developing a deeper understanding of T2DM’s complexities. The collaborative effort displayed by Wang and colleagues exemplifies how interdisciplinary research can lead to breakthroughs in patient care and disease management.

In summary, the integration of the triglyceride-glucose index with novel anthropometric metrics provides an innovative framework for predicting mortality risk in patients with T2DM. This research paves the way for improved assessments of diabetes-related health risks, ultimately influencing both clinical practice and patient outcomes in meaningful ways. By embracing this new approach, healthcare providers can enhance their capacity to combat the multifaceted challenges posed by diabetes, thereby saving lives and improving health in a substantial manner.

With the critical findings presented in this study, we stand on the precipice of a new era in diabetes management. The ramifications of utilizing these combined health indicators in clinical settings could herald significant advancements in how we approach the prevention and treatment of complications associated with type 2 diabetes, marking an important step towards achieving better health outcomes for millions worldwide.

As we look to the future, the research conducted by Wang, Wu, Mo, and their colleagues serves as a clarion call for further investigation into the biomarkers that can shape interventions for chronic diseases. The health community must now take these findings and translate them into effective clinical strategies that genuinely address the intricacies of patient care in the context of T2DM.

With the exciting potential of the triglyceride-glucose index coupled with novel anthropometric measures laid bare, the call to action is clear: let us harness these insights, advocate for their implementation in routine practice, and work tirelessly to empower patients managing type 2 diabetes to achieve healthier, more fulfilling lives.

Subject of Research: Predicting mortality risk in patients with T2DM using triglyceride‑glucose index and anthropometric measures.

Article Title: Combining triglyceride‑glucose index and novel anthropometric measures to predict mortality risk in patients with T2DM: a prospective cohort study.

Article References:

Wang, Y., Wu, F., Mo, H. et al. Combining triglyceride‑glucose index and novel anthropometric measures to predict mortality risk in patients with T2DM: a prospective cohort study.
BMC Endocr Disord (2026). https://doi.org/10.1186/s12902-025-02132-7

Image Credits: AI Generated

DOI:

Keywords: Triglyceride-glucose index, type 2 diabetes mellitus, mortality risk, anthropometric measures, prospective cohort study.

The study details how the TyG index serves as a reliable marker for assessing metabolic dysfunction. High levels of triglycerides combined with elevated glucose readings often reflect an underlying state of insulin resistance, a hallmark of metabolic syndrome. This correlation indicates more than just a coincidental relationship; it places the TyG index at the forefront of metabolic disorder diagnostics. By quantifying triglycerides alongside glucose levels, researchers can forge a clearer picture of a patient’s metabolic health.

Metabolic syndrome itself is a multifaceted disorder characterized by a cluster of conditions, including hypertension, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels. This constellation of symptoms not only increases the risk for cardiovascular disease but also heightens the likelihood of developing type 2 diabetes. The urgency to decipher the mechanisms driving metabolic syndrome is bolstered by alarming global trends in obesity and lifestyle-related illnesses. Researchers are now focusing on inflammatory markers and adipokines, which play critical roles in metabolic regulation.

Inflammation is increasingly recognized as a central player in metabolic syndrome. The study posits that elevated inflammatory markers, which can be readily measured through various laboratory tests, may provide insight into the inflammatory status of individuals with metabolic syndrome. This association suggests that individuals with high TyG indices are likely to experience increased levels of pro-inflammatory cytokines, which may exacerbate insulin resistance and worsen metabolic health.

Furthermore, dysregulation of adipokines, which are signaling proteins secreted by adipose tissue, is highlighted in the research. Adipokines have diverse roles in modulating metabolism and the immune response. The study reveals that patients with metabolic syndrome often exhibit altered profiles of these proteins, contributing to both systemic inflammation and metabolic derangement. The interplay between adipokine levels and the TyG index thus represents an important area for understanding the pathophysiology of metabolic syndrome.

Researchers argue that addressing these inflammatory shifts could pave the way for potential therapeutic interventions aimed at mitigating the consequences of metabolic syndrome. For instance, lifestyle modifications such as dietary changes and increased physical activity may not only help reduce triglyceride and glucose levels but could also positively influence inflammatory markers and adipokine profiles. This presents an opportunity for integrated treatment strategies focusing on reducing the TyG index while simultaneously managing inflammation.

Crucially, the study opens avenues for further exploration into how specific dietary components or pharmacological treatments might effectively lower both the TyG index and associated inflammatory markers. For instance, omega-3 fatty acids, known for their anti-inflammatory properties, are becoming the subject of rigorous investigation in this context. Additionally, the role of plant-based diets high in fiber may serve as another focal point for research on their ability to combat inflammation and improve metabolic health.

With the rise of personalized medicine, understanding the individual variations in inflammatory responses and adipokine production becomes critically important. The TyG index could serve as a valuable tool for clinicians aiming to tailor interventions based on specific patient profiles. The deployment of advanced machine learning algorithms might facilitate this personalization, helping predict responses to dietary or pharmaceutical interventions.

Moreover, the research underscores the importance of awareness among healthcare professionals regarding the implications of the TyG index. Clinicians armed with this knowledge can better screen and identify patients at risk for metabolic syndrome, offering early interventions that could alter disease trajectories. Educating both practitioners and patients about the audacity of the TyG index, as well as its implications for inflammation and metabolic regulation, is imperative in combating this growing health crisis.

As the evidence mounts linking the TyG index to inflammatory pathways in metabolic syndrome, it advocates for more extensive longitudinal studies. These future research endeavors will be pivotal in confirming the robustness of the TyG index as a biomarker and its potential in conjunction with other emerging indicators of metabolic health. Investigating genetic predispositions alongside environmental factors may further illuminate the variances observed in metabolic syndrome presentations, potentially guiding novel therapeutic avenues.

Continuing this line of inquiry, the research articulates the need for public health initiatives aimed at promoting awareness and prevention of metabolic syndrome. With rising global obesity rates and associated health complications, an integrated approach that combines dietary education, physical activity, and monitoring of metabolic markers like the TyG index could yield significant benefits. This multifaceted engagement stands to empower individuals towards achieving better metabolic health outcomes.

In conclusion, the study by Hamedi-Shahraki et al. significantly advances our understanding of the interconnected nature of the triglyceride-glucose index, inflammatory markers, and adipokine dysregulation in metabolic syndrome. The insights offered through their research could serve as a catalyst for future innovations in diagnostic strategies and treatment modalities. As we strive to unravel the complexities of metabolic health, this study reaffirms the importance of a comprehensive approach that amalgamates scientific inquiry with practical applications in clinical settings.

Subject of Research: The relationship between the triglyceride-glucose index and inflammatory markers in patients with metabolic syndrome.

Article Title: Association of the triglyceride-glucose index with inflammatory markers and dysregulation of adipokines in patients with metabolic syndrome.

Article References:

Hamedi-Shahraki, S., Klisic, A., Amirkhizi, F. et al. Association of the triglyceride-glucose index with inflammatory markers and dysregulation of adipokines in patients with metabolic syndrome.
BMC Endocr Disord (2026). https://doi.org/10.1186/s12902-025-02142-5

Image Credits: AI Generated

DOI: 10.1186/s12902-025-02142-5

Keywords: triglyceride-glucose index, inflammatory markers, adipokines, metabolic syndrome, insulin resistance, obesity, cardiovascular disease.